Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL): Adding Steam to ASCT

Authors :: Jonathan E. Brammer
Marcin Puto
Kami J. Maddocks
Ashley Elizabeth Rosko
Qiuhong Zhao
Samantha Jaglowski
Joseph Maakaron
Yvonne Efebera
Jayalakshmi Balakrishna
Ayman Saad
Beth Christian
Sam Penza
Basem M. William
John C. Reneau
Source :: Transplantation and Cellular Therapy. 27:S402-S403
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Oncology
Transplantation
medicine.medical_specialty
Venetoclax
business.industry
Cell Biology
Hematology
chemistry.chemical_compound
chemistry
Internal medicine
Relapsed refractory
Dose escalation
medicine
Molecular Medicine
Immunology and Allergy
Hodgkin lymphoma
Stem cell
business

Tools